New Wildlife

New Wildlife is a biotechnology company developing a new class of medicines to restore organ function through in vivo cellular reprogramming. The company's technology aims to reset the epigenetic state of cells to a more youthful and functional condition, potentially reversing the damage caused by aging and chronic disease. By targeting the underlying cellular mechanisms of organ failure, New Wildlife seeks to provide curative treatments for conditions that currently have limited therapeutic options. Based in San Francisco, the company is backed by a syndicate of top-tier venture capital firms including 8VC, Spark Capital, and Andreessen Horowitz.